RESUMEN
Objective: recent studies have reported dysregulated expression of matrix metalloproteinases [MMPs], especially MMP-2, MMP-9, tissue inhibitor of metalloproteinase-1, -2 [TIMP-1, TIMP-2], and extracellular matrix metalloproteinase inducer [EMMPRIN/CD147] in activated macrophages of patients with inflammatory diseases. Therefore, MMP-2, MMP-9, and their regulators may represent a new target for treatment of inflammatory diseases. Probiotics, which are comprised of lactic acid bacteria, have the potential to modulate inflammatory responses. In this experimental study, we investigated the anti-inflammatory effects of cell-free supernatants [CFS] from Lactobacillus acidophilus [L.acidophilus] and L. rhamnosus GG [LGG] in phorbol myristate acetate [PMA]-differentiated THP-1 cells
Materials and Methods: in this experimental study, PMA-differentiated THP-1 cells were treated with CFS from L. acidophilus, LGG and uninoculated bacterial growth media [as a control]. The expression of MMP-2, MMP-9, TIMP-1, and TIMP-2 mRNAs were determined using real-time quantitative reverse transcription polymerase chain reaction [RTPCR]. The levels of cellular surface expression of CD147 were assessed by flow cytometry, and the gelatinolytic activity of MMP-2 and MMP-9 were determined by zymography
Results: our results showed that CFS from both L. acidophilus and LGG significantly inhibited the gene expression of MMP-9 [P=0.0011 and P=0.0005, respectively], increased the expression of TIMP-1 [P<0.0001], decreased the cell surface expression of CD147 [P=0.0307 and P=0.0054, respectively], and inhibited the gelatinolytic activity of MMP-9 [P=0.0003 and P<0.0001, respectively] in PMA-differentiated THP-1 cells. Although, MMP-2 expression and activity and TIMP-2 expression remained unchanged
Conclusion: our results indicate that CFS from L. acidophilus and LGG possess anti-inflammatory properties and can modulate the inflammatory response
RESUMEN
Needle free vaccines have a several advantages and very attractive way for vaccination. In a body, mucosal surfaces provide a universal entry portal for all the known and emerging infectious pathogenic microbes. Therefore, it seems, vaccination strategies need to be reorganized for vaccines that are hindering the entry capability of pathogenic microbes through mucosal surfaces. Lactic acid Bacteria [LAB] are widely used in the food industry and at the present, used as delivery vehicles for biological investigations. In this review, we summarized the Results of several studies which Lactococcus lactis [L. lactis] used as a live vector for vaccines. These bacteria are considered as promising candidates for heterologous expression of proteins and biotechnological usage. LAB are considered as promising candidates for heterologous expression of proteins and biotechnological usage. The results showed that these bacteria have an ability to deliver antigen to immune system. Therefore, developing mucosal live vaccines using lactic acid bacterium, L. lactis, as an antigen delivery vector, is an attractive alternative choice and a safer vaccination strategy against pathogens